We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The attorneys general of Illinois and New York have subpoenaed Abbott Laboratories for information to be used in investigations of the company’s decision to increase the price of its HIV drug Norvir nearly fivefold, the drugmaker has revealed.
In a financially strategic move, Pfizer is expected this spring to introduce a new product that combines two of the firm’s top-selling drugs — its cholesterol drug Lipitor (atorvastatin calcium) and its high blood pressure drug Norvasc (amlodipine besylate).
Wyeth Pharmaceuticals and Forest Laboratories have revealed that the federal Office of Personnel Management (OPM) has issued subpoenas for documents relating to antidepressants marketed by the two drugmakers.
Faced with a barrage of international news stories, Aventis said last week it would file a report with the FDA about the deaths of five Japanese patients participating in a postmarketing study of its rheumatoid arthritis drug Arava, although the company contends there is no clear evidence the drug caused the fatalities.
While one group of U.S. researchers recently released a report finding that antidepressants like Prozac, Zoloft and Paxil do not raise the risk of suicide in children, other researchers claimed last week that drug companies’ refusal to release details of negative studies denies physicians and parents critical information needed to assess the safety of such drugs.
Cigna, one of the largest employer-sponsored health benefits providers, saved its members $12 million on prescription drug costs in 2003 through generic drug conversion programs, the firm said.
Following similar actions in other states, the attorney general of Arkansas has sued generic firms Dey and Warrick Pharmaceuticals, as well as Warrick’s affiliates Schering-Plough and Schering, for misreporting their average wholesale prices (AWPs), allegedly fraudulently inflating Medicaid and Medicare reimbursement rates to physicians and other providers.
With a new patent law coming into force next year, as well as a pool of cheap yet highly skilled scientists, India could become one of the top pharmaceutical manufacturing centers in the world, attracting the attention of both generic and brand firms, experts say.
Maine has finally launched its prescription drug discount plan that uses the state’s buying power under Medicaid to leverage lower prices from drug manufacturers.
Generic firm Synthon is free to launch a variation of GlaxoSmithKline’s (GSK’s) profitable antidepressant Paxil (paroxetine HCl) after the firms settled a patent dispute over the drug.